Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-risk Populations in Uganda, Africa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria (for HIV-uninfected volunteers):~* Willing to comply with the protocol and available for follow-up for the study duration~* Has understood the information provided and has provided written informed consent before any study-related procedures are performed~* Willing to undergo couple HIV testing, sexually transmitted infection (STI) screening, HIV counseling and receive test results, and share results with partner~* At risk for HIV infection as defined by: has an HIV-infected partner not using ART in the past 3 months and had episodes of unprotected sex with partner in the past 3 months~* If a female of childbearing potential:~  * using an effective method of non-barrier contraception (hormonal contraceptive~ * intrauterine device (IUD)~ * surgical sterility) from 7 days prior to randomization until the end of the study~ * all female volunteers must be willing to undergo urine pregnancy tests~* HIV-infected partner is willing and eligible to enroll in the study~Inclusion Criteria (for HIV-1 infected partner):~* HIV-1 infected partner of an HIV-uninfected volunteer who meets study eligibility~* Plan to remain in the relationship for the duration of the study period~* Willing and able to provide written informed consent \& locator information~Exclusion Criteria (for HIV-uninfected volunteer):~* Confirmed HIV-1 or HIV-2 infection~* Any clinically significant acute or chronic medical condition that is considered progressive, including severe infections requiring treatment such as tuberculosis, and alcohol or drug abuse~* Any of the following abnormal lab parameters:~  * Haemoglobin \< 9.0 g/dL~ * Creatinine clearance \<80mL/min, as calculated by Cockcroft-Gault equation~ * AST: \> 2.5 x ULN~ * ALT: \> 2.5 x ULN~ * Total bilirubin \> 1.5 x ULN~ * Serum amylase \> 1.5 x ULN~ * Serum phosphorus \< 2.4 mg/dL~ * Urinalysis: Two abnormal dipsticks showing any of the following:~    * blood = 2+ or more (not due to menses);~   * protein = 1+ or more~   * leucocytes = 2+ or more~   * glucose= 1+ or more~* Confirmed diagnosis of chronic hepatitis B infection (HBsAg positive)~* If female, pregnant or planning a pregnancy within 4 months after enrolment or lactating~* Participation in another clinical study of a product currently, or within the 3 mo. prior to enrolment~Exclusion Criteria (for HIV-1 infected partner):~* Current use of antiretroviral therapy~* Concurrent enrollment in another HIV treatment trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- FTC/TDF Daily (Type: EXPERIMENTAL): Daily dosing
- FTC/TDF Intermittent (Type: EXPERIMENTAL): Dosed intermittently
- Placebo Daily (Type: PLACEBO_COMPARATOR): Placebo dosed daily
- Placebo Intermittent (Type: PLACEBO_COMPARATOR): Placebo dosed intermittently, orally.

Based on this trial design, predict the completion outcome and termination type (if applicable).